Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

28.52
+0.44001.57%
Post-market: 28.00-0.5200-1.82%19:30 EDT
Volume:848.79K
Turnover:24.39M
Market Cap:3.24B
PE:-11.48
High:29.30
Open:28.46
Low:28.13
Close:28.08
52wk High:30.06
52wk Low:8.67
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.61
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:6.17
PE(LYR):-11.73

Loading ...

Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus

Simply Wall St.
·
Jul 18

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Simply Wall St.
·
Jul 17

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

TIPRANKS
·
Jul 11

Immunome Chief Business Officer Horn Kinney Disposes of 1,092 Common Shares Worth $27,300

Reuters
·
Jul 10

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

TIPRANKS
·
Jul 09

Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA

TIPRANKS
·
Jul 08

Immunome Flags Press Release on FDA Acceptance of Varegacestat NDA for Desmoid Tumors

Reuters
·
Jul 08

Immunome - Pdufa Target Action Date for Varegacestat Set for April 28, 2027

THOMSON REUTERS
·
Jul 08

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

THOMSON REUTERS
·
Jul 08

Immunome CMO Robert Lechleider Sells USD 1.27 Million in Common Shares

Reuters
·
Jul 08

Immunome Grants 344,000 Inducement Stock Options Priced at $21.49 Per Share

Reuters
·
Jul 08

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 08

Immunome Director Isaac Barchas Disposes of 201,050 Common Shares Worth $4.4 Million

Reuters
·
Jul 03

Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile

TIPRANKS
·
Jun 30

Immunome Chief Medical Officer Robert Lechleider Disposes of 55,000 Common Shares Worth $1.09 Million

Reuters
·
Jun 30

Immunome’s New Radiopharma Trial Puts IMNM on Early Oncology Watchlists

TIPRANKS
·
Jun 19

Immunome CFO Max Rosett disposes of 60,000 common shares worth $1.09 million

Reuters
·
Jun 18

Immunome shareholders reaffirm board, auditor and pay policies

TIPRANKS
·
Jun 13

Immunome shareholders elect three Class III directors at annual meeting

Reuters
·
Jun 13

Immunome (IMNM) Receives a Buy from Wedbush

TIPRANKS
·
Jun 13